Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
44.40
+0.05 (0.11%)
Mar 24, 2026, 1:30 PM CST
Market Cap3.94B -36.7%
Revenue (ttm)7.67M -1.0%
Net Income-258.40M
EPS-2.92
Shares Out88.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume116,007
Average Volume327,150
Open44.95
Previous Close44.35
Day's Range44.40 - 45.10
52-Week Range39.75 - 76.50
Beta0.45
RSI42.12
Earnings DateFeb 26, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.

Financial Statements